STING1 and systemic lupus erythematosus: However, its potency is a double-edged sword, with under-activation leading to an inadequate response to threats, such as cancer or viruses, and its over-activation is associated with the development of inflammatory and autoimmune diseases, such as systemic lupus erythematosus (SLE) [191], Aicardi–Goutières syndrome (AGS), STING-associated vasculopathy with onset in infancy (SAVI) [192], and neurodegenerative diseases [193].